IMS 2025 | Performance of a novel prognostic index for multiple and smoldering myeloma

The revolution in multiple myeloma is continuing. This is not only in therapeutic approach but also in important monitoring chains. And in my institution we are continuing to better understand how the biology of multiple myeloma is. The idea of the heterogeneity of disease we are going to study better integrating in our daily evaluation of Sky 92 panel. We want to develop a molecular approach that in a second phase should take to a target-driven approach in order to personalize the cure. We are going to integrate this data arising from a GEP project, so gene expression profiling, aiming to develop a new prognostic index together with the new generation imaging data. Whole body MRI is going to be combined in our consecutive patients, both frontline, relapsed/refractory, and high-risk smoldering myeloma is going to be combined to conventional PET/CT approach. And in our experience we have seen here the update presented at Toronto IMS in 2025, in 25 percent, one patient in four, this changed totally the outcome and permits to switch to a new treatment or to start previously the treatment according to the data of the addition of whole body MRI. This can change the journey of our patient. This can help in some way to optimize the treatment that we have available and I think that according to the amount of drugs that we are receiving, to invest also in improving the diagnostic tools for our patients is something that we have really to consider if you want really to cure and destroy multiple myeloma.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.